Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol

Griffiths, Kristi R.; Yang, Jenny; Touyz, Stephen; Hay, Phillipa; Clarke, Simon; Korgaonkar, Mayuresh S.; Gomes, Linette; Anderson, Gail; Foster, Sheryl; Kohn, Michael

doi:10.1186/s40337-019-0253-3

Cited by 19 publications

(21 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, imaging studies in those with binge eating describe dysfunctional fronto‐striatal regions that relate to reward‐based decision‐making and inhibition. Currently, little is known about whether stimulants reduce binge eating symptoms by influencing these neural systems; however, there are ongoing studies examining such hypotheses (e.g., Griffiths et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa

Keshen

Dixon

Ali

et al. 2021

Intl J Eating Disorders

View full text Add to dashboard Cite

Objective This study examined the feasibility, safety, and potential efficacy of lisdexamfetamine (LDX) as a treatment for adults with bulimia nervosa (BN). Method An open‐label 8‐week feasibility study was conducted in participants with BN. Enrollment rate, dropout rate, safety outcomes, and eating disorder symptom change were examined. Results Eighteen of 23 participants completed the study per protocol. There was no participant‐initiated dropout due to adverse drug reactions and no severe and unexpected adverse drug reactions. An average increase in heart rate of 12.1 beats/min was observed. There was a mean weight reduction of 2.1 kg and one participant was withdrawn for clinically significant weight loss. In the intent‐to‐treat sample, there were reductions in objective binge episodes and compensatory behaviors from Baseline to Post/End‐of‐Treatment (mean difference = −29.83, 95% confidence interval: −43.38 to −16.27; and mean difference = −33.78, 95% confidence interval: −48.74 to −18.82, respectively). Discussion Results of this study indicate that a randomized controlled trial would be feasible with close monitoring of certain safety parameters (especially over a longer time period as long‐term safety is unknown). However, the results should not be used as evidence for clinicians to prescribe LDX to individuals with BN before its efficacy and safety are properly tested. Trial Registration Number NCT03397446.

show abstract

Section: Discussionmentioning

confidence: 99%

A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa

Keshen

Dixon

Ali

et al. 2021

Intl J Eating Disorders

View full text Add to dashboard Cite

show abstract

“…Further, Lisdexamfetamine dimesylate (LDX) has been suggested to regulate the dopamine and noradrenaline neurotransmitter systems that are involved in eating behaviour and reward regulation, and thus decrease binge eating [ 48 ]. LDX is also the only approved medication for adults with BED by the US Food and Drug Administration (FDA) [ 49 , 50 ]. Thus, both these drugs can also be considered to address food-related impulsivity, even though the impulsivity concept was not explicitly included in the articles as a supposed working mechanism.…”

Section: Discussionmentioning

confidence: 99%

Can we change binge eating behaviour by interventions addressing food-related impulsivity? A systematic review

İnce

Schlatter²,

Max

et al. 2021

J Eat Disord

View full text Add to dashboard Cite

Background An extensive amount of research has underlined the potential role of impulsivity in the development and maintenance of binge eating behaviour. Food-related impulsivity has particularly received attention given its close relationship with overeating and binge eating episodes. Besides the available evidence, our understanding regarding the effectiveness of treatment modalities for binge eating targeting impulsivity and related constructs (e.g., food craving, inhibitory control, and reward sensitivity) is limited. Thus, this systematic review aimed to investigate whether binge eating behaviour is changeable by interventions that are impulsivity-focused and food-related and whether one of these interventions is superior to the others. Method A search on PubMed and PsycINFO was performed for relevant articles published up to September 2020. Studies delivering food-related impulsivity treatment to individuals suffering from binge eating episodes and including a control condition without this treatment were investigated. Following the search, 15 studies meeting the eligibility criteria were analysed. Results Analyses revealed that available impulsivity-focused approaches can be categorised as psychotherapy, pharmacotherapy, computer-assisted cognitive training, and direct neuromodulation interventions. Regarding their effectiveness, it appeared that all of these approaches might be promising to change food-related impulsivity in individuals with binge eating episodes, particularly to decrease binge eating symptoms. However, a superior intervention approach in this early state of evidence could not be determined, although food-related cue exposure, transcranial direct current stimulation, and the combination of several interventions seem fruitful. Conclusion Efforts to treat binge eating behaviour with interventions focusing on food-related impulsivity appear to be promising, particularly concerning binge eating frequency, and also for food craving and inhibitory control. Given limited research and varying methods, it was not possible to conclude whether one impulsivity-focused intervention can be considered superior to others.

show abstract

“…The concomitant use of psychological therapies (e.g., CBT) and some medications can induce superior outcomes for BED than either treatment alone 61,62 . The only agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe BED in adults is lisdexamfetamine dimesylate—a drug originally used in the treatment of attention‐deficit hyperactivity disorder 63 . The safety and efficacy of lisdexamfetamine dimesylate in the treatment of BED for up to 12 months were shown in a multicenter, double‐blind, placebo‐controlled randomized clinical trial 64–67 .…”

Section: Cognitive Behavior Therapy (Cbt) For Bed Including Cbt Enhamentioning

confidence: 99%

The treatment of binge eating disorder with cognitive behavior therapy and other therapies: An overview and clinical considerations

et al. 2020

View full text Add to dashboard Cite

Summary Binge eating disorder (BED) is a public health problem in several countries. BED is commonly associated with comorbidities such as obesity, diabetes, and depression. Notwithstanding the health problems associated with BED, evidence‐based treatments for BED are not widely used by healthcare professionals worldwide. Thus, we provide an overview of the leading evidence‐based psychological therapies for BED, with the intention of informing healthcare professionals and the general community and facilitating greater provision of treatment. Cognitive behavior therapy (CBT) for BED is briefly presented, focusing mainly on adaptations and stages of the cognitive behavior therapy‐enhanced (CBT‐E) transdiagnostic model for eating disorders. We also succinctly discuss the use of CBT in combination with weight management interventions or pharmacotherapy, as well as the use of interpersonal therapy and dialectical behavior therapy for BED. We conclude that there is a variety of evidence‐based psychological therapies that can be used by a variety of healthcare professionals (not only by psychologists) to help reduce binge eating and associated psychopathology in people with BED. Given the high and increasing prevalence of BED, as well as the availability of effective evidence‐based treatments, we encourage more healthcare professionals to explore up‐skilling to assist people with BED.

show abstract

Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol

Cited by 19 publications

References 53 publications

A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa

A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa

Can we change binge eating behaviour by interventions addressing food-related impulsivity? A systematic review

The treatment of binge eating disorder with cognitive behavior therapy and other therapies: An overview and clinical considerations

Contact Info

Product

Resources

About